Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 07 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Oxantel pamoate–albendazole for infection with soil-transmitted helminths

Treatment with oxantel pamoate–albendazole resulted in higher cure and egg-reduction rates for T. trichiura infection than the rates with standard therapy, reports this week's issue of the New England Journal of Medicine.

News image

Infections with soil-transmitted helminths (Ascaris lumbricoides, hookworm, and Trichuris trichiura) are widespread and often occur concomitantly.

These parasitic-worm infections are typically treated with albendazole or mebendazole, but both drugs show low efficacy against Trichuris trichiura.

Albendazole is the drug of choice against hookworm.

In this double-blind trial conducted on Pemba Island, Tanzania, Dr Benjamin Speich and colleagues randomly assigned children, 6 to 14 years of age, to receive one of 4 treatments.

The treatments included oxantel pamoate at a dose of 20 mg per kilogram of body weight, plus 400 mg of albendazole, administered on consecutive days, oxantel pamoate at a single dose of 20 mg per kilogram, albendazole at a single dose of 400 mg, or mebendazole at a single dose of 500 mg.

The researchers assessed the efficacy and safety profile of oxantel pamoate–albendazole when used in the treatment of Trichuris trichiura infection, and concomitant soil-transmitted helminth infection.

Adverse events were reported by 31% of all children
Alimentary Pharmacology & Therapeutics

Efficacy was determined by means of assessment of the cure rate and egg-reduction rate.

The team assessed adverse events were 4 times after treatment.

Complete data were available for 458 children, of whom 450 were infected with T. trichiura, 443 with hookworm, and 293 with A. lumbricoides.

The team observed that the cure rate of Trichuris trichiura infection was significantly higher with oxantel pamoate–albendazole than with mebendazole, as was the egg-reduction rate.

The cure rate and the egg-reduction rate was significantly lower than the rates with mebendazole.

Oxantel pamoate had low efficacy against hookworm and A. lumbricoides.

Adverse events were reported by 31% of all children.

Dr Speich's team concludes, "Treatment with oxantel pamoate–albendazole resulted in higher cure and egg-reduction rates for Trichuris trichiura infection than the rates with standard therapy."

N Engl J Med 2014; 370:610-620
14 February 2014

Go to top of page Email this page Email this page to a colleague

 05 February 2016 
Methotrexate and remission in ulcerative colitis
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's
 15 January 2016 
Alcohol- and HCV-related hepatocellular carcinoma
 15 January 2016 
Recurrent colonic diverticulitis
 15 January 2016 
Colonic diverticula and colorectal cancer risk
 14 January 2016 
Risk stratification of incidentally discovered gallstones
 14 January 2016 
Treatment of refractory cholestatic pruritus
 14 January 2016 
Colonic diverticula and colorectal cancer risk 
 13 January 2016 
C-section delivery and IBD risk
 13 January 2016 
Primary biliary cholangitis treatment with incomplete UDCA response
 13 January 2016 
Colon cancer screening rates 
 12 January 2016 
Eosinophilic esophagitis endoscopic reference score
 12 January 2016 
Web-based tool for Crohn's disease
 12 January 2016 
IBD patients willingnes to accept medication risk
 11 January 2016 
HCV and increased cardiovascular mortality
 11 January 2016 
Urinary tract cancers in IBD
 11 January 2016 
Race and eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us